Pelago Bioscience AB and OmicScouts GmbH launched a commercial and scientific collaboration involving the use of the Cellular Thermal Shift Assay (CETSA™) for determination and quantification of drug-target interactions, according to BioSpace.com.
Under the agreement, Pelago Bioscience grants OmicScouts use licenses to the CETSA method for mass spectrometric and proteomic applications for contract research projects adding to its broad portfolio of mass spec-based proteomics technologies. The collaboration will allow Pelago Bioscience to extend and add value to the existing service portfolio on target engagement determinations and analysis in cells and tissue, notes BioSpace.com.
Both companies plan to scientifically and technologically explore and develop the CETSA method for proteomics applications for drug de-orphanization and biomarker discovery applications, says BioSpace.com. Other terms and financial details of the agreement were not disclosed.
“The active and strategic collaboration with OmicScouts will allow us to provide customers with improved proteomics applications of the CETSA method. I believe that mass spec applications of CETSA will revolutionize the profiling of both candidate drugs from target based and phenotypic screening based drug discovery,”’ says Michael Dabrowski, CEO of Pelago Bioscience.
Hannes Hahne, Managing Director at OmicScouts commented: “We are convinced that CETSA with proteomic readout can nicely complement chemical proteomics techniques for target identification and offers unprecedented perspectives to study small molecule-protein interactions,” adds Hannes Hahne, managing director at OmicScouts.